Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 43.68M P/E - EPS this Y - Ern Qtrly Grth -
Income -78.62M Forward P/E -1.32 EPS next Y - 50D Avg Chg 15.00%
Sales 338k PEG - EPS past 5Y - 200D Avg Chg -32.00%
Dividend N/A Price/Book 0.39 EPS next 5Y - 52W High Chg -89.00%
Recommedations 2.00 Quick Ratio 3.82 Shares Outstanding 4.58M 52W Low Chg 68.00%
Insider Own 21.01% ROA -33.02% Shares Float 2.92M Beta 2.77
Inst Own 22.71% ROE -111.07% Shares Shorted/Prior 69.89K/111.73K Price 0.99
Gross Margin - Profit Margin - Avg. Volume 70,845 Target Price -
Oper. Margin -18,017.46% Earnings Date Aug 13 Volume 34,635 Change 5.81%
About Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Senti Biosciences, Inc. News
12/16/24 Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
12/05/24 Senti Bio price target raised to $12 from $10 at Chardan
12/03/24 Senti Biosciences Announces New Employment Inducement Grants
12/03/24 SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
12/03/24 Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202
12/02/24 Sector Update: Health Care Stocks Slipping Late Afternoon
12/02/24 Why Is Senti Biosciences Stock Surging Over 400% On Monday?
12/02/24 Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
12/02/24 Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
12/02/24 Senti Bio Appoints Fran Schulz to Board of Directors
11/14/24 Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
09/03/24 Senti Bio to Participate in Upcoming Investor Conferences
08/13/24 Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
08/05/24 Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
07/16/24 Senti Bio Announces Reverse Stock Split
07/01/24 Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
05/13/24 Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
05/09/24 Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
04/30/24 Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
03/21/24 Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
SNTI Chatroom

User Image Kale Posted - 10 hours ago

$NKGN you can see that this is being manipulated to only allow it to creep up slowly. This moves with very little volume Looking for an $SNTI like run here. I would like to Hear them state that they are expanding to include AML and other solid tumors like melanoma

User Image Faroose Posted - 13 hours ago

$PTIX gonna give a legendary end of the year run like $SNTI

User Image Z_interceptor Posted - 15 hours ago

$SNTI + I'm your daddy! +

User Image LetsMoon Posted - 1 day ago

$SNTI Monday pop?

User Image Kale Posted - 1 day ago

$NKGN I believe we can see an $SNTI like run here

User Image MindFuck Posted - 1 day ago

$SNTI This one always has a morning glory and then goes down to even lower prices. Faking it every day Mo-Fr

User Image RAPIDTRADX Posted - 2 days ago

$SNTI KEEP 👀

User Image jjhar Posted - 2 days ago

$SNTI Don't freak out, the new SEC filing is outlining the PIPE offering that was announced on Dec 2nd. However, there is new info in there that allowed me to confirm more information about this line from the PR: "The Company has also granted to a certain investor an option to purchase an additional 4,444 shares of Preferred Stock and accompanying warrants for gross proceeds of approximately $10.0 million at a subsequent closing to occur no later than December 27, 2024." This investor has the option to buy more preferred stock and unexercised warrants that would grant them ~6,666,000 common shares at a $2.3 strike price. This is in addition to the unexercised warrants already owned by all PIPE investors that can result in 25,069,500 common shares. We'll know by Dec 27th if this investor elects to exercises this option. The company would net another $10m if they do. Lastly, while exercised warrants will dilute, they will also raise another $73m for the SNTI. Hope this helps someone!

User Image Mertle Posted - 2 days ago

$SNTI Average volume & price has been holding and only going up with $TNXP. More watchers/investors everyday, as well as more long term holders with belief in double digit possibilities. I think people will sell around $2, $5, $10, $20, $40. I plan on keeping a few thousand for future products or some huge buyout.

User Image MindFuck Posted - 2 days ago

@tallguy777 naaah try $SNTI 🤣😂

User Image LetsMoon Posted - 2 days ago

$SNTI this could bounce to $7 anytime

User Image jjhar Posted - 2 days ago

$SNTI As I continue my DD, the PIPE deal terms are likely driving the SP down. Here's why: -4.8m shares are outstanding right now -25m additional shares can be exercised via warrants provided to the pipe investors (upon shareholder approval) -This would be a 6x increase in the number of shares (30m), a very very large dilution -I can't find the strike price the warrants would be exercised at but given the timing of the announcement it is probably around $1.5-3 -Now let's say for argument sake the strike price is $1.5, if the stock is trading at $4 when the shares are exercised, there will be a rush of selling until it reaches $1.5 (or in the ballpark of), as a chunk of these pipe investors will likely want to lock in some profits -Keep in mind that in this scenario where the shares outstanding inc to 30m and the SP dips to $1.5, the MC increases to $45m. -So basically, this logic suggests current investors are speculating on the strike price of the warrants, which is driving down the SP

User Image AbhiSg Posted - 2 days ago

$SNTI Every single day it touches a New Bottom. No Hopes Left

User Image AbhiSg Posted - 2 days ago

$SNTI Hopeless. Helpless. Worst decision.

User Image Kamie123 Posted - 2 days ago

$SNTI wtfffff

User Image jjhar Posted - 3 days ago

$SNTI I was planning to wait a few weeks but if this drops to the $3.10 range before the new year, it's an obvious buy with a right sized position. No more than 0.5% of my portfolio for something of this MC

User Image BioTechChap Posted - 3 days ago

$SNTI Reminds me of ALGS 3 months ago. It’s a matter of time before we see low volume flat SP action followed by a major Bullish trend. Patience pays off, ain’t no easy

User Image AbhiSg Posted - 3 days ago

$SNTI why Blood Bath ? 18th day of getting constantly dip

User Image AbhiSg Posted - 4 days ago

$SNTI https://www.dailymail.co.uk/health/article-14198851/russia-cancer-vaccine-development-details-free.html

User Image LetsMoon Posted - 4 days ago

$SNTI lots of short positions, no fear?

User Image jjhar Posted - 4 days ago

$SNTI A minimum of 4 weeks away from hearing any news about the first patient dosed for HCC. My assumption is that more than likely they will want to dose a couple patients before making an announcement but maybe someone else knows more than me about how this company operates. "Three dose levels of SN301A will be administered in cycles, each comprising of 3 weekly doses (Days 0, 7, 14) during a 28-day treatment cycle following a standard lymphodepletion conditioning regimen of fludarabine and cytarabine."

User Image biolover Posted - 4 days ago

$SNTI if one patient with HCC responds to this very sophisticated approach. It could be the most undervalued opportunity in biotech

User Image London718 Posted - 5 days ago

$LAES $SNTI

User Image Courtcourt15216 Posted - 5 days ago

$LAES $SNTI

User Image FinanceForever Posted - 5 days ago

$LAES not even close this is a legit company with ties to SpaceX unlike $SNTI which is a scam

User Image LewisDaKat Posted - 5 days ago

$SNTI News Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics https://marketwirenews.com/news-releases/senti-bio-announces-first-patient-dosed-in-clinical--6191576147038328.html $SNTI

User Image AbhiSg Posted - 5 days ago

$SNTI $10 seems light years away now

User Image AbhiSg Posted - 5 days ago

$SNTI i am so depressed. i bought this at $10.34 in FOMO and since that day, it never seen in Green. No News is helping it to move upwards. i am loosing all my money. Depressed 😔

User Image Dragonfly41 Posted - 5 days ago

$SNTI CAPR Huge FDA BLA submission news coming this week

User Image LetsMoon Posted - 5 days ago

$SNTI didn’t catch the dip…man…

Analyst Ratings
Chardan Capital Buy Aug 15, 23
Chardan Capital Buy May 11, 23
Morgan Stanley Equal-Weight Mar 24, 23
Chardan Capital Buy Mar 23, 23
Chardan Capital Buy Jan 30, 23
Morgan Stanley Equal-Weight Jan 27, 23
JP Morgan Neutral Dec 16, 22
Morgan Stanley Equal-Weight Oct 7, 22
B of A Securities Buy Sep 29, 22